Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

BioXcel Therapeutics

NASDAQ BTAI
$2.35 -0.16 -6.81%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 19 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

69.21M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
104.93M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.05
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
29.45M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-20.34 %

Upcoming events BioXcel Therapeutics

All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart BioXcel Therapeutics

Stock analysis BioXcel Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-0.39 27.69
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
-1.22 3.65
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-0.61 9.48
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
-0.21 -0.16
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
313.73 7.67

Price change BioXcel Therapeutics per year

23.07$ 67.74$
Min Max

Summary analysis BioXcel Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure BioXcel Therapeutics

Revenue and net income BioXcel Therapeutics

All parameters

Stock news BioXcel Therapeutics

All news
13 February в 18:14

BioXcel Therapeutics Shares Rise 13% After Public Offering Terminated

13 February в 18:14

BioXcel Therapeutics Shares Rise 13% After Public Offering Terminated

12 February в 15:35

BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation

12 February в 15:30

BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation

9 February в 02:30

BioXcel Therapeutics Shares Drop After Launching $60 Million Public Offering

9 February в 02:30

BioXcel Therapeutics Shares Drop After Launching $60 Million Public Offering

5 February в 16:15

BioXcel Therapeutics Shares Rise 12% After U.S. Patent Allowance

5 February в 16:15

BioXcel Therapeutics Shares Rise 12% After U.S. Patent Allowance

14 November 2023 в 17:30

BioXcel Therapeutics Shares Sink After Weak 3Q

14 November 2023 в 17:30

BioXcel Therapeutics Shares Sink After Weak 3Q

30 October 2023 в 20:05

BioXcel Therapeutics Shares Rise 29% After Getting J-Code for Igalmi

30 October 2023 в 20:00

BioXcel Therapeutics Shares Rise 29% After Getting J-Code for Igalmi

25 October 2023 в 16:30

BioXcel Therapeutics shares pop after audit of Alzheimer’s trial data

25 October 2023 в 15:50

BioXcel Therapeutics shares pop after audit of Alzheimer’s trial data

25 October 2023 в 15:20

BioXcel Therapeutics Jump Premarket After Positive Audit of Trial Data Integrity

25 October 2023 в 15:15

BioXcel Therapeutics Jump Premarket After Positive Audit of Trial Data Integrity

10 October 2023 в 19:50

BioXcel Therapeutics Shares Rise 14% After Positive Trial Data for Cancer Treatment

10 October 2023 в 19:50

BioXcel Therapeutics Shares Rise 14% After Positive Trial Data for Cancer Treatment

14 August 2023 в 15:15

BioXcel Therapeutics to cut workforce 58%, stock falls 27%

14 August 2023 в 14:25

BioXcel Therapeutics to Cut Nearly 60% of Workforce

About company BioXcel Therapeutics

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Address:
555 Long Wharf Drive, New Haven, CT, United States, 06511
Company name: BioXcel Therapeutics
Issuer ticker: BTAI
ISIN: US09075P1057
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2018-03-08
Sector: Healthcare
Industry: Biotechnology
Site: https://www.bioxceltherapeutics.com

On which stock exchange are BioXcel Therapeutics (BTAI) stocks traded?

BioXcel Therapeutics (BTAI) stocks are traded on NASDAQ.

What is the ticker of BioXcel Therapeutics stocks (BTAI)?

The stock ticker of BioXcel Therapeutics’s stocks or in other words, the code is BTAI. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does BioXcel Therapeutics (BTAI) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, BioXcel Therapeutics (BTAI) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are BioXcel Therapeutics (BTAI) stocks traded?

BioXcel Therapeutics (BTAI) stocks are traded on the NASDAQ exchange in dollars.

What is the price of BioXcel Therapeutics (BTAI) stocks today?

The current price of BioXcel Therapeutics stocks on 08.05.2024 is 2.35 dollars. per share.

What is the dynamics of BioXcel Therapeutics (BTAI) stocks from the beginning of the year?

BioXcel Therapeutics (BTAI) quotes have increased by -19.8% from the beginning of the year up to 2.35 dollars. per 1 stocks.

How much did BioXcel Therapeutics (BTAI) stocks increase in мае 2024?

This month BioXcel Therapeutics (BTAI) quotes have increased by -7.48% to 2.35 dollars. per share.

How much are BioXcel Therapeutics (BTAI) stocks worth?

Today, on October, 08.05.2024 BioXcel Therapeutics’s (BTAI) stocks cost 2.35 dollars..

What is the market capitalization of BioXcel Therapeutics (BTAI)?

Capitalization is the market value of BioXcel Therapeutics (BTAI) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 08.05.2024, the market capitalization of BioXcel Therapeutics (BTAI) is estimated at about 69205150 dollars.